Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

BACKGROUND: EGFR mutation is a strong predictive factor of EGFR-TKIs therapy. However, at least 10% of patients with EGFR wild-type are responsive to TKIs, suggesting that other determinants of outcome besides EGFR mutation might exist. We hypothesized that activation of phosphorylated EGFR could be...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fen, Wang, Shuhang, Wang, Zhijie, Duan, Jianchun, An, Tongtong, Zhao, Jun, Bai, Hua, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548765/
https://www.ncbi.nlm.nih.gov/pubmed/22901364
http://dx.doi.org/10.1186/1756-9966-31-65

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3548765/
https://www.ncbi.nlm.nih.gov/pubmed/22901364
http://dx.doi.org/10.1186/1756-9966-31-65

Ejemplares similares